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Abstract
Introduction Clinicians are in need of better diagnostic markers
in diagnosing infections and sepsis. We studied the ability of
procalcitonin, lipopolysaccharide-binding protein, IL-6 and C-
reactive protein to identify patients with infection and sepsis.
Methods Plasma and serum samples were obtained on
admission from patients with suspected community-acquired
infections and sepsis. Procalcitonin was measured with a time-
resolved amplified cryptate emission technology assay.
Lipopolysaccharide-binding protein and IL-6 were measured
with a chemiluminescent immunometric assay.
Results Of 194 included patients, 106 had either infection
without systemic inflammatory response syndrome or sepsis.
Infected patients had significantly elevated levels of
procalcitonin, lipopolysaccharide-binding protein, C-reactive
protein and IL-6 compared with noninfected patients (P  <
0.001). In a receiver-operating characteristic curve analysis, C-
reactive protein and IL-6 performed best in distinguishing
between noninfected and infected patients, with an area under
the curve larger than 0.82 (P < 0.05). IL-6, lipopolysaccharide-
binding protein and C-reactive protein performed best in
distinguishing between systemic inflammatory response
syndrome and sepsis, with an area under the curve larger than
0.84 (P < 0.01). Procalcitonin performed best in distinguishing
between sepsis and severe sepsis, with an area under the curve
of 0.74 (P < 0.01).
Conclusion C-reactive protein, IL-6 and lipopolysaccharide-
binding protein appear to be superior to procalcitonin as
diagnostic markers for infection and sepsis in patients admitted
to a Department of Internal Medicine. Procalcitonin appears to
be superior as a severity marker.
Introduction
Sepsis is a common condition affecting an increasing number
of hospitalized patients [1]. The prevalence of severe sepsis
among inpatients varies between 2% and 11% [2]. Sepsis can
be difficult to distinguish from other conditions causing sys-
temic inflammatory response syndrome (SIRS) [3,4]. For the
appropriate management of patients presenting with SIRS it is
important to be able to distinguish between infectious and
noninfectious causes as early as possible. This might help
identify patients who need antibiotic treatment and help to
avoid using antibiotics in those without infection.
C-reactive protein (CRP) has been used as a marker of infec-
tion for many years. Elevated CRP levels are seen in infection,
in autoimmune disease, in cancer, in trauma and in surgery [5].
Other markers have recently been introduced as possible can-
didates for use in clinical practice. Procalcitonin (PCT) is a
protein that has been proposed as a sensitive and specific
marker of sepsis. Elevated levels of PCT have been associated
with severe bacterial infections among children and adults [6].
Contrary to most other markers evaluated in the past, PCT has
been reported to be specific in discriminating between viral
infection and bacterial sepsis [7]. The origin and biological
function of PCT in severe infection is not clarified.
AUC = area under the curve; 95% CI = 95% confidence interval; CRP = C-reactive protein; IL = interleukin; LBP = lipopolysaccharide-binding pro-
tein; PCR = polymerase chain reaction; PCT = procalcitonin; ROC = receiver-operating characteristic; SIRS = systemic inflammatory response syn-
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Lipopolysaccharide-binding protein (LBP) is an acute-phase
protein that has been suggested as a marker of infection [8].
This protein has a role in the innate immune response. It binds
to lipopolysaccharide and thereafter brings lipopolysaccharide
to the CD14 receptors on the monocyte-macrophage cell lin-
eage. CD14 receptors then interact with Toll-like receptor-4,
initiating cytokine production [9,10]. LBP has a longer half-life
than the cytokines it induces [11]. These aspects make it inter-
esting to evaluate LBP in infection and sepsis.
High levels of IL-6 have been associated with severe inflamma-
tion and sepsis [12-15]. IL-6 has a central role in inducing the
synthesis of acute-phase proteins such as CRP and LBP [16].
IL-6 elevations are seen earlier than the elevation of the afore-
mentioned acute-phase proteins. This makes IL-6 an interest-
ing molecule to evaluate in the early phase of infection and
sepsis.
An ideal marker of infection and sepsis should have several
qualities. A high sensitivity will ensure that all infected patients
have a positive result, and a high specificity is required to avoid
that patients without infection are diagnosed as having an
infection. Furthermore, it should be possible to analyze the
marker in a rapid assay with high accuracy.
We have previously shown that CRP and IL-6 are better mark-
ers of infection and severity of infection than soluble hemo-
globin scavenger receptor (sCD163) in a population of
patients admitted to a Department of Internal Medicine [17]. In
the present study we examined and compared the perform-
ance of CRP and IL-6 with that of PCT and LBP in the same
population of patients. We used assays that all could be per-
formed in a routine Department of Clinical Biochemistry.
Methods
Patients
Patients were included in a prospective manner in the period
January–May 2003. The patients were referred by a general
practitioner or were admitted from the Emergency Room.
Odense University Hospital is a 1,200 bed health care facility
serving a local population of approximately 185,000 inhabit-
ants. The study setting was a Department of Internal Medicine
covering the specialties of infectious diseases, rheumatology,
pulmonary medicine and general internal medicine. Inclusion
criteria for study were suspected diagnosis of infection as
judged by the referring physician and blood cultures drawn at
the time of admission. The exclusion criteria were age <18
years, earlier participation in the study or prior hospitalization
within seven days before admission. Plasma for later analyses
Table 2
Outcome of the patients
Variable Noninfected without 
SIRS (n = 48)
Noninfected with 
SIRS (n = 19)
Infection without 
SIRS (n = 32)
Sepsis 
(n = 47)
Severe sepsis 
(n = 27)
Hospitalization (days) 8.4 ± 6.7 8.7 ± 7.8 10.3 ± 11.5 7.8 ± 6.7 10.8 ± 10.5
Mortality on day 28 2 (4.2) 4 (21.1) 0 0 4 (14.8)
Data are presented as the absolute number (%) or the mean ± standard deviation. SIRS, systemic inflammatory response syndrome.
Table 1
Baseline characteristics of the patients
Variable Noninfected without 
SIRS (n = 48)
Noninfected with 
SIRS (n = 19)
Infection without 
SIRS (n = 32)
Sepsis 
(n = 47)
Severe sepsis 
(n = 27)
Male 16 (33.3) 7 (36.8) 18 (56.3) 20 (42.6) 18 (66.7)
Female 32 (66.6) 12 (63.2) 14 (43.7) 27 (57.4) 9 (33.3)
Age 68.4 ± 18 64.4 ± 14.6 60.8 ± 16.6 60.4 ± 19.9 66.4 ± 17.8
SOFA score 1.3 ± 1.1 1.7 ± 1.1 1.6 ± 1.5 1.6 ± 1.2 3.0 ± 1.9
Charlson Index of comorbidity 1.5 ± 1.3 1.9 ± 1.2 1.3 ± 1.3 1.1 ± 1.3 1.2 ± 1.3
Hemoglobin (mmol/l) 7.9 ± 1.0 8.5 ± 1.1 8.2 ± 1.2 8.2 ± 1.2 8.2 ± 1.1
Platelet count (109/l) 291 ± 115.5 283 ± 89.1 325 ± 210.6 254 ± 107.3 268 ± 184.4
Bilirubin (µmol/l) 9.3 ± 6.7 9.5 ± 7.6 21.9 ± 36.6 10.6 ± 6.8 13.6 ± 5.5
Prothrombin time 1.0 ± 0.3 0.9 ± 0.3 0.9 ± 0.4 0.9 ± 0.3 0.9 ± 0.3
Creatinine (µmol/l) 96.9 ± 27.1 96.1 ± 28.5 100.6 ± 31.2 100.4 ± 31.7 140.3 ± 79.5
Data are presented as the absolute number (%) or the mean ± standard deviation. SIRS, systemic inflammatory response syndrome; SOFA, 
Sepsis-related Organ Failure Assessment.Available online http://ccforum.com/content/10/2/R53
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of PCT, LBP and IL-6 were drawn immediately after admission.
The samples were processed and frozen at -80°C within 1.5
hours. Sampling was performed before any antibiotic treat-
ment was started at the hospital. The patients received a
standard of care according to the departmental guidelines.
The project protocol was approved by the Ethics Committee
of Fyns and Vejle Counties. Informed consent was obtained
from all patients or their close relatives.
Baseline characteristics, demographic data, biochemical
parameters, SIRS criteria and severity score were obtained at
the time of inclusion. Severity was assessed with the Sepsis-
related Organ Failure Assessment score [18]. Comorbidity
was assessed with the Charlson Index [19]. Patients were
classified at the time of admission according to the SIRS cri-
teria [3]. Severe sepsis was defined as the presence of sepsis
and one or several of the following indices of organ dysfunc-
tion: Glasgow coma scale ≤14, PaO2 ≤9.75 kPa, oxygen sat-
uration ≤92%, PaO2/FiO2 ≤250, systolic blood pressure ≤90
mmHg, systolic blood pressure fall ≥40 mmHg from baseline,
pH ≤7.3, lactate ≥2.5 mmol/l, creatinine ≥177 µmol/l, 100%
increase of creatinine in patients with known kidney disease,
oliguria  ≤30 ml/hour in >3 hours or ≤0.7 l/24 hours, pro-
thrombin time ≤0.6 (reference: 0.70–1.30), platelets ≤100 ×
109/l, bilirubin ≥43 µmol/l, and paralytic ileus. Septic shock
was defined as hypotension persisting despite adequate fluid
Table 4
Diagnoses of the non-infected patients (n = 67)
Diagnosis Number of patients
Central nervous system disease 5
Cardiovascular disease 10
Respiratory disease 33a
Gastroenterological disease 2
Hematological disease 2
Malignant disease 4
Rheumatological disease 8
Renal disease 1
Dehydration 2
aChronic obstructive pulmonary disease (n = 22).
Table 3
Microbiological and infection characteristics of the patients
Variable Infection without SIRS (n = 32) Sepsis (n = 47) Severe sepsis (n = 27)
Assessment of infection (n)
Gram-positive bacteria 6 12 10
Gram-negative bacteria 7 10 7
Other bacteria 0 2a 0
Bacteremia 1 4 7
Virus 3b 4c 1d
Chest X-ray-verified pneumoniae 91 3 7
Radiological evidencef 01 0
Obvious clinical infectiong 75 2
Focus of infection (n)
Upper respiratory tract infection 1 0 1
Lower respiratory tract infection 12 25 15
Endocarditis 1 0 1
Gastroenteritis 5 1 0
Pyelonephritis 2 2 1
Cystitis 0 3 3
Skin/soft tissue infection 1 4 3
Bone/joints 2 1 0
Other 8 11 3
SIRS, systemic inflammatory response syndrome. aMycoplasma pneumoniae (n = 2). bEpstein–Barr virus (n = 1), influenzae A virus (n = 2). 
cEpstein–Barr virus (n = 2), influenza A virus (n = 2). dPuumala virus (n = 1). eChest X-ray-verified pneumonia with no identified pathogen. 
fInfection documented by imaging techniques (other than Chest X-ray) with no identified pathogen. gClinical infection (i.e. erysipelas, wound 
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resuscitation for at least 1 hour. If a patient had any comorbid-
ity that could more probably explain one or more of the criteria
for organ dysfunction stated earlier, the patient could not be
categorized as having severe sepsis.
Infection was categorized according to the following defini-
tions: culture/microscopy of a pathogen from a clinical focus;
positive urine dip test in the presence of dysuria symptoms;
chest X-ray-verified pneumonia with no identified pathogen;
infection documented with another imaging technique with no
identified pathogen; obvious clinical infection (for instance,
erysipelas, wound infection); and identification of a pathogen
by serology or PCR. The classification of the status of infection
was made by a single physician who was blinded to all bio-
chemical laboratory results. The patients were divided into the
following groups for the subsequent statistical analyses: non-
infected patients without SIRS, noninfected patients with
SIRS, infected patients without SIRS, patients with sepsis,
and patients with severe sepsis/septic shock. Patients who
could not be classified were excluded from the analyses.
Laboratory assays
PCT was measured with a time-resolved amplified cryptate
emission technology assay (Kryptor PCT®; Brahms, Hen-
nigsdorf, Germany). The functional assay sensitivity was 0.06
ng/ml. LBP and IL-6 were measured with a chemiluminescent
immunometric assay (Immulite-1000®; DPC, Los Angeles,
CA, USA). The detection limit of LBP was 0.2 µg/ml. The
detection limit of IL-6 was 2 pg/ml. CRP was measured with
an immunoturbidometric principle (Modular P®; Hitachi,
Tokyo, Japan). White blood cells and neutrophils were
counted on a Sysmex SE 9000® (TOA®, Kobe, Japan). PCT,
LBP and IL-6 measurements were carried out in duplicate and
the mean values were used for analyses.
Statistical analysis
Data are presented as medians, interquartile ranges and
means ± standard deviation. Significance testing was carried
out using the Kruskal–Wallis test. A two-tailed P value < 0.05
was considered statistically significant. Receiver-operator
characteristic (ROC) curves and the area under the curve
Table 5
Levels of procalcitonin, lipopolysaccharide-binding protein, C-reactive protein, IL-6, white blood cells and neutrophils in different 
groups
Variablea Noninfected without 
SIRS (n = 48)
Noninfected with 
SIRS (n = 19)
Infection without 
SIRS (n = 32)
Sepsis 
(n = 47)
Severe sepsis 
(n = 27)
Procalcitonin (ng/ml)
Median 0.07 0.09 0.16 0.2 1.9
Interquartile range 0.05–0.11 0.05–0.14 0.07–0.34 0.08–0.65 0.22–14.6
Lipopolysaccharide-binding protein (µg/ml)
Median 16.3 16.4 27.4 33.5 40.4
Interquartile range 12.6–25.3 11.3–26.5 18.3–41.2 25.0–43.2 18.0–63.6
C-reactive protein (mg/l)
Median 18.0 19.0 122.0 120.0 217.0
Interquartile range 10.0–38.0 10.0–65.0 54.0–215.0 41.0–190.0 78.0–414.0
IL-6 (pg/ml)
Median 8.7 9.8 20.6 72.6 199.3
Interquartile range 3.2–20.7 2.0–23.7 9.8–99.4 25.9–274.5 67.5–2833.0
White blood cells (109/l)
Median 7.8 9.5 9.5 13.0 12.2
Interquartile range 6.7–9.2 7.8–12.1 7.7–11.9 9.2–17.1 7.0–17.5
Neutrophils (109/l)
Median 5.9 7.6 7.1 10.1 10.3
Interquartile range 4.6–6.9 6.2–9.8 5.1–9.7 7.1–14.8 5.5–15.4
SIRS, systemic inflammatory response syndrome. aP < 0.001 by the Kruskal–Wallis test.Available online http://ccforum.com/content/10/2/R53
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(AUC) were determined for PCT, LBP, IL-6, CRP, white blood
cells and neutrophils. AUC values are reported with the 95%
confidence interval (95% CI). The method described by
DeLong and colleagues was used as the significance test for
ROC and AUC comparison [20]. Sensitivities, specificities,
positive predictive values and negative predictive values were
calculated from cross-tabulations. The positive likelihood ratio
and negative likelihood ratio were also reported.
Prior to the study we chose the following cut off levels for
reporting sensitivities, specificities, positive predictive values,
negative predictive values, positive likelihood ratios and nega-
tive likelihood ratios: PCT, 0.1 ng/ml, 0.25 ng/ml and 0.5 ng/
ml; LBP, 20 µg/ml and 40 µg/ml; CRP, 50 mg/l and 100 mg/
l; and IL-6, 25 pg/ml and 50 pg/ml. We also planned to report
cut off levels, specificities, positive predictive values, negative
predictive values, positive likelihood ratios and negative likeli-
hood ratios with sensitivities of approximately 80%. We
intended to compare the test performance by comparing the
AUCs and by comparing the specificities when the sensitivity
was approximately 80%. The Spearman rank correlation test
was used to determine correlations. At the time of the study
the Department of Clinical Biochemistry did not report levels
of CRP below 10 mg/l; CRP measurements below 10 mg/l
were therefore assigned a value of 10 mg/l for calculations.
The detection limit of our method for IL-6 measurements was
2 pg/ml; IL-6 measurements below 2 pg/ml were therefore
assigned a value of 2 pg/ml for calculations. Statistical calcu-
lations were performed in STATA 8 (STATA Corporation®,
College Station, TX, USA).
Results
Patient characteristics
One hundred and ninety-four adult patients were included in
our study. The patients were divided according to our defini-
tions into the following groups: 48 noninfected patients with-
out SIRS, 19 noninfected patients with SIRS, 32 infected
patients without SIRS, 47 patients with sepsis, and 27
patients with severe sepsis or septic shock. Only one patient
had septic shock. This patient was included in the severe sep-
sis group. Twenty-one patients could not be classified and
were excluded from analyses. Fifteen (22.4%) of the nonin-
fected patients were treated with prednisolone and one
treated with methotrexate at the time of admission. Fifteen
(14.2%) of the infected patients were treated with pred-
nisolone at the time of admission. The baseline characteristics,
the outcome, and the microbiology and focus of infection are
presented in Tables 1, 2, 3. The final diagnoses of the nonin-
fected patients are described in Table 4.
Levels of PCT, LBP, IL-6 and CRP
The levels of PCT, LBP, IL-6 and CRP were statistically signif-
icantly higher among all infected patients compared with non-
infected patients (P < 0.001) (Table 5). There was a small
increase in PCT levels from the group of noninfected patients
to the group of infected patients without SIRS and to the
group of sepsis patients. Patients with severe sepsis had
almost 10-fold higher levels of PCT compared with patients
with sepsis. Levels of LBP, IL-6 and CRP increased progres-
sively with increasing severity of infection/sepsis.
Figure 2
ROC curves comparing inflammatory markers discriminating abilities  between systemic inflammatory response syndrome and sepsis(P 2  0.01). Receiver-operating characteristic (ROC) curves comparing pro- calcitonin (pct), lipopolysaccharide-binding protein (lbp), C-reactive  protein (crp), IL-6 (il6), white blood cell (wbc) and neutrophil (neutro)  discriminating abilities between systemic inflammatory response syn- drome (SIRS) (noninfected with SIRS) and sepsis (sepsis and severe  sepsis) (P < 0.01) ROC curves comparing inflammatory markers discriminating abili-
ties between systemic inflammatory response syndrome and sep-
sis(P 2 0.01). Receiver-operating characteristic (ROC) curves 
comparing procalcitonin (pct), lipopolysaccharide-binding protein (lbp), 
C-reactive protein (crp), IL-6 (il6), white blood cell (wbc) and neutrophil 
(neutro) discriminating abilities between systemic inflammatory 
response syndrome (SIRS) (noninfected with SIRS) and sepsis (sepsis 
and severe sepsis) (P < 0.01).
Figure 1
ROC curves comparing inflammatory markers discriminating abilities  between noninfected patients and all infected patients (P < 0.05).  Receiver-operating characteristic (ROC) curves comparing procalci- tonin (pct), lipopolysaccharide-binding protein (lbp), C-reactive protein  (crp), IL-6 (il6), white blood cell (wbc) and neutrophil (neutro) discrimi- nating abilities between noninfected patients and all infected patients  (P < 0.05) ROC curves comparing inflammatory markers discriminating abili-
ties between noninfected patients and all infected patients (P < 
0.05). Receiver-operating characteristic (ROC) curves comparing pro-
calcitonin (pct), lipopolysaccharide-binding protein (lbp), C-reactive 
protein (crp), IL-6 (il6), white blood cell (wbc) and neutrophil (neutro) 
discriminating abilities between noninfected patients and all infected 
patients (P < 0.05).Critical Care    Vol 10 No 2    Gaïni et al.
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Diagnostic performance of PCT, LBP, IL-6, CRP, white blood
cell count and neutrophils in diagnosing infection, sepsis and
severe sepsis
In a ROC analysis to distinguish between noninfected patients
and infected patients, CRP and IL-6 had the highest AUC val-
ues of 0.83 (95% CI 0.76–0.89) and 0.82 (95% CI 0.75–
0.88) (Figure 1). PCT performed with an AUC of 0.77 (95%
CI 0.69–0.84) and LBP with an AUC of 0.78 (95% CI 0.71–
0.85) (Figure 1). Using a cut off level of 30 mg/l, CRP had a
sensitivity of 80.2% and a specificity of 62.7% in diagnosing
infection (Table 6). Using a cut off level of 16.3 pg/ml, IL-6 had
a sensitivity of 79.2% and a specificity of 64.2% in diagnosing
infection (Table 6).
In a ROC analysis to distinguish between patients with nonin-
fectious SIRS and patients with sepsis/severe sepsis, IL-6,
LBP and CRP had an AUC of 0.87 (95% CI 0.78–0.96), 0.86
(95% CI 0.77–0.95) and 0.84 (95% CI 0.75–0.92), respec-
tively (Figure 2). PCT had an AUC of 0.75 (95% CI 0.63–
0.87) (Figure 2). Using a cut off level of 25 pg/ml, IL-6 had a
sensitivity of 81.1% and a specificity of 78.9% in diagnosing
sepsis/severe sepsis (Table 7). Using a cut-off level of 20 µg/
ml, LBP had a sensitivity of 81.0% and a specificity of 68.4%
in diagnosing sepsis/severe sepsis (Table 7). Using a cut off
level of 38 mg/l, CRP had a sensitivity of 79.7% and a specif-
icity of 57.9% in diagnosing sepsis/severe sepsis (Table 7).
In a ROC analysis to distinguish between patients with sepsis
and patients with severe sepsis, PCT performed best with an
AUC of 0.74 (95% CI 0.61–0.87) (Figure 3).
Correlations between the examined markers
A strong correlation was found between LBP and CRP (r =
0.842,  P  < 0.0001) and a weaker correlation was found
between LBP and IL-6 (r = 0.568, P < 0.0001). Weak corre-
lations were found between PCT, CRP and IL-6.
Discussion
The patients included in this study were elderly patients with a
burden of comorbidity representative of medical patients
admitted to a Department of Internal Medicine. The mortality
among the infected patients was only 3.8% and the severity of
sepsis was low as judged by the Sepsis-related Organ Failure
Assessment score. Our patients therefore had relatively mild
disease compared with patients included in most other diag-
nostic test studies focusing on infection and sepsis [21-27].
This study therefore adds valuable information on markers of
sepsis.
If new diagnostic markers are considered for introduction in
nonintensive care patients or patients with less severe disease
it is important that they are validated in the relevant population.
Our study population was well characterized and the study
had a prospective design. We avoided workup bias by blind-
Table 6
Sensitivity, specificity, positive predictive value, negative predictive value, positive likelihood ratio and negative likelihood ratio of 
inflammatory markers in diagnosing infection
Variable Cut-off level Sensitivity (%) Specificity (%) Positive 
predictive 
value (%)
Negative 
predictive 
value (%)
Positive 
likelihood 
ratio
Negative 
likelihood 
ratio
Procalcitonin 0.075 ng/ml 80.2 47.8 70.8 60.4 1.5 0.41
0.1 ng/ml 71.6 62.7 75.3 58.3 1.9 0.45
0.25 ng/ml 48.1 89.5 87.9 52.2 4.6 0.58
0.5 ng/ml 37.7 95.5 93.0 49.2 8.4 0.65
Lipopolysaccha
ride-binding 
protein
20 µg/ml 78.3 64.2 77.6 65.2 2.2 0.34
40 µg/ml 37.7 91.0 86.9 48.0 4.2 0.68
C-reactive 
protein
30 mg/l 80.2 62.7 77.3 66.7 2.2 0.32
50 mg/l 73.6 74.6 82.1 64.1 2.9 0.35
100 mg/l 62.3 89.5 90.4 60.0 5.9 0.42
IL-6 16.3 pg/ml 79.2 64.2 77.8 66.2 2.2 0.32
25 pg/ml 70.8 77.6 83.3 62.6 3.2 0.38
50 pg/ml 58.5 88.0 88.6 57.3 4.9 0.47Available online http://ccforum.com/content/10/2/R53
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ing the physician scoring the infection status from all biochem-
ical laboratory results. We tried to minimize spectrum bias by
using relatively liberal inclusion criteria. We used a sensitive
PCT assay that made it possible also to determine PCT levels
between 0.06 ng/ml and 0.5 ng/ml. This made it possible to
examine lower cut off levels for PCT, which was important
since we studied less ill patients where we could expect lower
PCT levels than those reported among patients in intensive
care units. Our definition of infection did not exclude patients
with viral infection.
There were eight confirmed cases with viral infection, and it is
possible that some patients where no pathogen was identified
had viral infection. In our opinion this reflects the clinical reality,
where often no etiological agent is identified despite thorough
clinical and laboratory investigations. A drawback in this study
design is the possibility of imperfect gold standard bias. If the
test and imperfect gold standard are independent we can
expect that the sensitivity and specificity of the test will be
underestimated. Because of the risk of imperfect gold stand-
ard bias, we also analyzed the diagnostic test abilities of our
candidate markers, after having excluded all patients without
microbiological proven infection. The results of these analyses
did not, however, lead to a different conclusion on the utility of
the candidate markers (data not shown).
The biological role of PCT has not yet been clarified [28].
Some studies have suggested PCT to be a secondary media-
tor involved in the immunopathogenesis in sepsis. Administra-
tion of PCT to septic hamsters increased mortality, and the
neutralization of PCT with antiserum to septic hamsters
reduced mortality [29]. This suggests that the highest levels of
PCT may be seen in severe sepsis with high mortality. The low
levels of PCT in our study probably reflect that we were focus-
ing on a population with relatively mild disease. It is possible
that elevated levels of PCT are mainly seen in patients with
severe sepsis with high Sepsis-related Organ Failure Assess-
ment scores and in patients with septic shock.
Several studies have focused on the diagnostic test abilities of
PCT to diagnose sepsis in patients requiring intensive care
[21-27]. These studies found sensitivities between 65% and
97% and specificities between 48% and 94%. Three of these
studies found PCT to be a better sepsis marker than CRP
[22,24,25]. In the study by Ugarte and colleagues, however,
CRP performed better than PCT [21]. Also, PCT and CRP
performed equally well in the study by Suprin and colleagues
[23]. Few studies have been conducted in patients not admit-
ted to intensive care units. These studies have found sensitiv-
ities between 24% and 74% and specificities between 70%
and 94% [30-34]. PCT was not a better marker of bacterial
infection than CRP in the study by Chan and colleagues [32].
PCT had a lower sensitivity and a higher specificity while CRP
had a higher sensitivity and a lower specificity in the study by
Stucker and colleagues [34].
These studies mentioned used less sensitive methods for PCT
analyses than in the present study. In our study PCT per-
formed poorer than CRP, IL-6 and LBP in diagnosing infection
and in discriminating between noninfectious SIRS and sepsis/
Table 7
Sensitivity, specificity, positive predictive value, negative predictive value, positive likelihood ratio and negative likelihood ratio of 
inflammatory markers in diagnosing sepsis
Variable Cut-off level Sensitivity (%) Specificity (%) Positive 
predictive 
value (%)
Negative 
predictive 
value (%)
Positive 
likelihood 
ratio
Negative 
likelihood 
ratio
Procalcitonin 0.087 ng/ml 79.7 42.1 84.3 34.8 1.4 0.48
0.1 ng/ml 75.7 52.6 86.2 35.7 1.6 0.46
0.25 ng/ml 55.0 89.5 95.4 34.0 5.2 0.5
0.5 ng/ml 45.9 89.5 94.4 29.8 4.4 0.6
Lipopolysaccha
ride-binding 
protein
20 µg/ml 81.0 68.4 90.9 48.2 2.6 0.28
40 µg/ml 41.9 100.0 100.0 30.7 0.58
C-reactive 
protein
38 mg/l 79.7 57.9 88.1 42.3 1.9 0.35
50 mg/l 71.6 63.2 88.3 36.4 1.9 0.45
100 mg/l 63.5 94.7 97.9 40.0 11.9 0.39
IL-6 25 pg/ml 81.1 78.9 93.8 51.7 3.8 0.24
50 pg/ml 70.3 89.5 96.3 43.6 6.7 0.33Critical Care    Vol 10 No 2    Gaïni et al.
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severe sepsis. In contrast, PCT performed best in a ROC anal-
ysis distinguishing between patients with sepsis and patients
with severe sepsis, supporting other findings of PCT being a
marker reflecting the severity of sepsis [21,22].
LBP has a central role in the early activation of the innate
immune response [9]. LBP, like CRP, is an acute-phase pro-
tein produced in the liver. Although the function of LBP is to
bind lipopolysaccharide from Gram-negative bacteria, ele-
vated levels of LBP are also seen in Gram-positive infections
[35]. This is an important observation if LBP is considered as
a marker for both Gram-negative infection and Gram-positive
infection. We found a strong correlation between LBP and
CRP suggesting a common activation or a common pathway
for these acute phase proteins.
A few studies have investigated LBP levels in infection and
sepsis [11,35-39]. To our knowledge only three studies have
focused on LBP diagnostic test abilities in severe infections
[37-39]. The study by Oude Nijhuis and colleagues found a
sensitivity of 100% and a specificity of 92% in diagnosing
Gram-negative bacteremia in cancer patients with neutropenia
[37]. They used a high cut off level (46.3 µg/ml) for LBP. The
study by Prucha and colleagues found a sensitivity of 50% and
a specificity of 74.2% in discriminating between noninfectious
SIRS and sepsis, in a cohort of patients requiring intensive
care [38]. The study by Pavcnik-Arnol and colleagues found a
sensitivity of 97% and a specificity of 70% in diagnosing sep-
sis in critically ill children [39]. In their study LBP performed
equally compared with CRP, but was superior to IL-6 and
PCT. Our data suggest that LBP performs better than PCT as
a diagnostic marker for infection and sepsis.
A correlation between IL-6 levels and the severity/mortality of
sepsis has been observed in several studies [13-15]. Sensitiv-
ities between 65.0% and 86.0% and specificities between
54.0% and 79.0% have been found in diagnosing sepsis [24-
26,40]. In three of these studies PCT was superior to IL-6
[24,26,40]. This is contrary to our data, which suggest that IL-
6 is superior to PCT as a diagnostic marker for infection and
sepsis.
Several studies have focused on the diagnostic test abilities of
CRP in diagnosing infection and/or sepsis [21,23-
25,30,32,34,41,42]. These studies found sensitivities
between 67.2% and 94.3% and specificities between 33.0%
and 93.9%. In our study CRP performed better than PCT as a
diagnostic marker for infection and sepsis.
A diagnostic marker of any disease should provide the clini-
cian with useful information to increase the likelihood of diag-
nosing either if the disease is actually present or if the disease
is in fact absent. Because prompt and effective antibiotic treat-
ment is crucial in the treatment of patients with infections and
sepsis, any new potential diagnostic marker of infection should
have a high sensitivity, so as many as possible of the infected
patients are diagnosed as early as possible. This may lead to
some overuse of antibiotics because of a lower specificity, but
in terms of consequence for the individual patient we consider
this to be a lesser concern than withholding antibiotics from
the infected patient.
Our study data suggest that LBP (cut off level 20 µg/ml), CRP
(cut off level 30 mg/l) and IL-6 (cut off level 16.3 pg/ml) are
comparable in terms of their diagnostic abilities in diagnosing
infection. A high sensitivity and a high specificity are also
important qualities that should be required from any new
potential diagnostic marker distinguishing between SIRS with-
out infection and sepsis. Our study data suggest that IL-6 with
a cut off level of 25 pg/ml has the best diagnostic abilities in
diagnosing sepsis. With this cut off level, IL-6 has a sensitivity
and a specificity of approximately 80%. An effective new
potential diagnostic marker could also have qualities in identi-
fying noninfected patients with or without SIRS. This would
require a high specificity. Our study data suggest that CRP
(cut off level 100 mg/l) and IL-6 (cut off level 50 pg/ml) have
the best qualities in identifying the noninfected patients. With
these cut off levels CRP and IL-6 have sensitivities higher than
58% and specificities greater than 88% in diagnosing infec-
tion.
Conclusion
Data from earlier studies and from our study suggest that the
markers examined in the present study can have different test
qualities depending on the study population. It is important to
look separately at the test qualities on an intensive care unit
population dominated by severe sepsis/septic shock, and
those on an internal medicine population, dominated by the
Figure 3
ROC curves comparing inflammatory markers discriminating abilities  between sepsis and severe sepsis (P 2 0.01). Receiver-operating char- acteristic (ROC) curves comparing procalcitonin (pct), lipopolysaccha- ride-binding protein (lbp), C-reactive protein (crp), IL-6 (il6), white  blood cell (wbc) and neutrophil (neutro) discriminating abilities  between sepsis and severe sepsis (P < 0.01) ROC curves comparing inflammatory markers discriminating abili-
ties between sepsis and severe sepsis (P 2 0.01). Receiver-operat-
ing characteristic (ROC) curves comparing procalcitonin (pct), 
lipopolysaccharide-binding protein (lbp), C-reactive protein (crp), IL-6 
(il6), white blood cell (wbc) and neutrophil (neutro) discriminating abili-
ties between sepsis and severe sepsis (P < 0.01).Available online http://ccforum.com/content/10/2/R53
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milder end of the sepsis spectrum. Our data suggest that PCT
does not have a diagnostic role in patients with mild infection/
sepsis admitted to a Department of Internal Medicine. IL-6,
CRP and LBP appear to be of equal value as diagnostic infec-
tion markers in our study. They performed better than PCT, but
are all relatively poor markers for infection with sensitivity/spe-
cificity below 80% with the chosen cut-off levels. IL-6, LBP
and CRP appear to be superior as diagnostic sepsis markers
compared with PCT. Only IL-6 reached a sensitivity and spe-
cificity of approximately 80% in diagnosing sepsis with a cut-
off level of 25 pg/ml.
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